| Literature DB >> 35163522 |
Dan Liu1, Ling Luo1, Zhengxing Wang1, Xiaoyun Ma2, Xiuhai Gan1.
Abstract
Plant diseases that are caused by fungi and nematodes have become increasingly serious in recent years. However, there are few pesticide chemicals that can be used for the joint control of fungi and nematodes on the market. To solve this problem, a series of novel 1,2,4-oxadiazole derivatives containing amide fragments were designed and synthesized. Additionally, the bioassays revealed that the compound F15 demonstrated excellent antifungal activity against Sclerotinia sclerotiorum (S. sclerotiorum) in vitro, and the EC50 value of that was 2.9 μg/mL, which is comparable with commonly used fungicides thifluzamide and fluopyram. Meanwhile, F15 demonstrated excellent curative and protective activity against S. sclerotiorum-infected cole in vivo. The scanning electron microscopy results showed that the hyphae of S. sclerotiorum treated with F15 became abnormally collapsed and shriveled, thereby inhibiting the growth of the hyphae. Furthermore, F15 exhibited favorable inhibition against the succinate dehydrogenase (SDH) of the S. sclerotiorum (IC50 = 12.5 μg/mL), and the combination mode and binding ability between compound F15 and SDH were confirmed by molecular docking. In addition, compound F11 showed excellent nematicidal activity against Meloidogyne incognita at 200 μg/mL, the corrected mortality rate was 93.2%, which is higher than that of tioxazafen.Entities:
Keywords: 1,2,4-oxadiazole; antifungal activity; nematicidal activity; succinate dehydrogenase
Mesh:
Substances:
Year: 2022 PMID: 35163522 PMCID: PMC8836147 DOI: 10.3390/ijms23031596
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Structures of reported antifungal and nematicidal compounds containing amide or 1,2,4-oxadiazole fragments, compounds 1 and 2 are from Zhang et al., 2018.
Figure 2Design of the target compounds.
Scheme 1Schematic representation of synthesis of target compounds F1–F24.
In vitro antifungal activity of the title compounds F1–F24 at 50 μg/mL.
| Compound | R | R′ |
| Inhibition Rate (%) a | |
|---|---|---|---|---|---|
|
| C6H5 | 2-Py | 2 | 24.2 ± 0.2 | 73.2 ± 0.1 |
|
| C6H5 | 3-Cl-5-CF3-2-Py | 2 | 23.6 ± 0.6 | 48.6 ± 1.6 |
|
| C6H5 | 2,4-di-F-C6H3 | 1 | 56.8 ± 0.1 | 84.8 ± 0.6 |
|
| C6H5 | 2,4-di-Cl-C6H3 | 0 | 20.9 ± 0.1 | 31.2 ± 0.7 |
|
| 4-CH3-C6H4 | 2-Py | 2 | 24.9 ± 1.6 | 56.3 ± 1.2 |
|
| 4-CH3-C6H4 | 3-Cl-5-CF3-2-Py | 2 | 22.9 ± 1.1 | 56.0 ± 1.4 |
|
| 4-CH3-C6H4 | 2,4-di-F-C6H3 | 1 | 46.4 ± 0.8 | 56.4 ± 0.1 |
|
| 4-CH3-C6H4 | 2,4-di-Cl-C6H3 | 0 | 22.7 ± 1.3 | 21.1 ± 1.7 |
|
| 4-Cl-C6H4 | 2-Py | 2 | 26.7 ± 0.5 | 61.1 ± 0.7 |
|
| 4-Cl-C6H4 | 3-Cl-5-CF3-2-Py | 2 | 24.2 ± 1.7 | 48.6 ± 1.2 |
|
| 4-Cl-C6H4 | 2,4-di-F-C6H3 | 1 | 44.2 ± 1.2 | 44.9 ± 0.9 |
|
| 4-Cl-C6H4 | 2,4-di-Cl-C6H3 | 0 | 29.1 ± 1.4 | 24.8 ± 1.4 |
|
| thienyl | 2-Py | 2 | 27.3 ± 0.4 | 41.1 ± 0.1 |
|
| thienyl | 3-Cl-5-CF3-2-Py | 2 | 36.4 ± 0.2 | 65.2 ± 0.2 |
|
| thienyl | 2,4-di-F-C6H3 | 1 | 58.2 ± 0.2 | 89.3 ± 0.4 |
|
| thienyl | 2,4-di-Cl-C6H3 | 0 | 25.5 ± 0.6 | 39.6 ± 0.1 |
|
| 6-Br-3-Py | 2-Py | 2 | 27.6 ± 1.4 | 10.1 ± 1.2 |
|
| 6-Br-3-Py | 3-Cl-5-CF3-2-Py | 2 | 55.9 ± 1.3 | 34.9 ± 1.1 |
|
| 6-Br-3-Py | 2,4-di-F-C6H3 | 1 | 42.2 ± 0.2 | 35.8 ± 0.8 |
|
| 6-Br-3-Py | 2,4-di-Cl-C6H3 | 0 | 55.8 ± 0.1 | 13.8 ± 0.5 |
|
| 3-Cl-5-CF3-2-Py | 2-Py | 2 | 38.8 ± 0.7 | 35.1 ± 0.1 |
|
| 3-Cl-5-CF3-2-Py | 3-Cl-5-CF3-2-Py | 2 | 45.2 ± 0.9 | 37.6 ± 1.9 |
|
| 3-Cl-5-CF3-2-Py | 2,4-di-F-C6H3 | 1 | 41.5 ± 0.5 | 34.6 ± 0.1 |
|
| 3-Cl-5-CF3-2-Py | 2,4-di-Cl-C6H3 | 0 | 38.5 ± 0.5 | 1.8 ± 0.8 |
| Fluopyram | 87.3 ± 0.6 | 93.7 ± 1.7 | |||
| Thifluzamide | 80.3 ± 0.2 | 86.7 ± 0.3 | |||
a Values are mean ± SD of three replicates.
The EC50 values of partial compounds against S. scleotiorum and the cytotoxicity in normal cells L-02.
| Compound | EC50 (μg/mL) a | 95% Confidence Interval | Regression Equation | R | Cytotoxicity (%) a | ||
|---|---|---|---|---|---|---|---|
| 200 μg/mL | 100 μg/mL | 50 μg/mL | |||||
|
| 20.8 ± 0.8 | 17.2–25.9 | Y = −2.4 + 1.9x | 0.95 | 15.4 ± 4.4 | 10.9 ± 5.9 | 4.7 ± 4.9 |
|
| 5.4 ± 0.3 | 4.0–6.8 | Y = −1.6 + 2.2x | 0.93 | 50.8 ± 3.9 | 17.0 ± 1.4 | 7.5 ± 3.8 |
|
| 18.7 ± 0.4 | 12.6–31.7 | Y = −1.4 + 1.1 x | 0.94 | 31.5 ± 8.7 | 7.1 ± 6.5 | −2.5 ± 0.2 |
|
| 15.3 ± 1.3 | 10.5–23.6 | Y = −1.3 + 1.1x | 0.99 | 39.1 ± 8.4 | 21.4 ± 5.0 | 18.8 ± 2.5 |
|
| 2.9 ± 1.3 | 1.6–4.1 | Y = −0.8 + 1.8x | 0.96 | 37.4 ± 0.2 | 11.3 ± 4.8 | 1.4 ± 2.2 |
| Fluopyram | 1.2 ± 1.6 | 0.7–2.0 | Y = −0.1 + 0.9x | 0.97 | 55.1 ± 0.4 | 40.1 ± 1.2 | 3.8 ± 2.5 |
| Thifluzamide | 4.3 ± 1.7 | 2.5–7.5 | Y = −0.5 + 0.9x | 0.94 | 33.9 ± 1.5 | 33.7 ± 0.4 | 33.3 ± 1.8 |
a Values are mean ± SD of three replicates.
Figure 3Inhibitory activity of compound F15 on mycelial growth of S. sclerotiorum.
In vivo curative and protective effects of compound F15 and fluopyram against S. sclerotiorum on infected cole leaves.
| Compound | Concentration (μg/mL) | Curative Effect | Protective Effect | ||
|---|---|---|---|---|---|
| Lesion Length (mm ± SD) | Control Efficacy (%) | Lesion Length (mm ± SD) | Control Efficacy (%) | ||
|
| 100 | 8.3 ± 0.7 | 62.3 | 6.9 ± 0.2 | 71.0 |
| 50 | 11.0 ± 0.4 | 50.0 | 8.1 ± 0.5 | 66.0 | |
| 25 | 15.9 ± 0.3 | 27.7 | 10.4 ± 0.7 | 56.3 | |
| Fluopyram | 100 | 5.7 ± 0.6 | 74.1 | 5.8± 0.1 | 75.6 |
| 50 | 6.3 ± 0.2 | 71.4 | 7.3 ± 0.2 | 69.3 | |
| 25 | 7.7 ± 0.6 | 65.0 | 7.9 ± 0.1 | 66.8 | |
| Control | – | 22.0 ± 0.8 | – | 23.8 ± 0.3 | – |
Figure 4The curative effect (A) and protective effect (B) of F15 against S. sclerotiorum.
In vitro nematicidal activity of compounds F1–F24.
| Compound | Corrected Mortality Rate ± SD (%) a | |||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
| |||||
| 200 µg/mL | 50 µg/mL | 200 µg/mL | 50 µg/mL | 200 µg/mL | 50 µg/mL | 200 µg/mL | 50 µg/mL | |
|
| 43.5 ± 2.3 | 6.9 ± 2.1 | 88.7 ± 1.3 | 51.3 ± 2.2 | 6.1 ± 1.1 | 0.0 | 6.9 ± 1.2 | 0.0 |
|
| 42.6 ± 3.6 | 7.4 ± 3.2 | 46.7 ± 2.6 | 10.3 ± 1.4 | 5.5 ± 1.6 | 0.0 | 15.1 ± 1.6 | 0.0 |
|
| 54.9 ± 3.3 | 13.9 ± 2.1 | 100.0 | 100.0 | 26.1 ± 1.2 | 0.0 | 20.1 ± 1.3 | 0.0 |
|
| 23.2 ± 1.4 | 5.9 ± 1.3 | 98.4 ± 2.3 | 71.4 ± 2.2 | 25.3 ± 1.7 | 0.0 | 11.7 ± 1.4 | 0.0 |
|
| 35.0 ± 2.2 | 3.5 ± 1.3 | 94.6 ± 1.7 | 67.9 ± 2.3 | 8.1 ± 2.2 | 0.0 | 22.5 ± 3.2 | 0.0 |
|
| 44.6 ± 3.8 | 7.9 ± 2.2 | 100.0 | 100.0 | 11.6 ± 2.1 | 0.0 | 29.4 ± 2.3 | 0.0 |
|
| 24.9 ± 3.2 | 5.3 ± 1.1 | 91.9 ± 2.5 | 68.2 ± 2.3 | 28.1 ± 2.4 | 0.0 | 12.2 ± 2.1 | 0.0 |
|
| 23.9 ± 3.3 | 4.9 ± 2.1 | 77.6 ± 1.2 | 47.6 ± 1.7 | 18.1 ± 1.2 | 0.0 | 6.1 ± 1.2 | 0.0 |
|
| 56.3 ± 2.4 | 9.8 ± 2.5 | 87.6 ± 1.1 | 62.1 ± 2.2 | 14.5 ± 2.5 | 0.0 | 12.8 ± 2.3 | 0.0 |
|
| 15.8 ± 3.5 | 0.0 | 100.0 | 69.3 ± 1.8 | 12.1 ± 1.7 | 0.0 | 23.6 ± 2.2 | 0.0 |
|
| 93.2 ± 2.1 | 24.8 ± 2.2 | 73.6 ± 1.7 | 10.6 ± 1.3 | 23.2 ± 2.1 | 0.0 | 19.8 ± 2.1 | 0.0 |
|
| 54.8 ± 2.5 | 13.8 ± 2.3 | 47.6 ± 1.2 | 8.6 ± 1.6 | 20.8 ± 2.5 | 0.0 | 18.8 ± 1.1 | 0.0 |
|
| 11.6 ± 1.1 | 0.0 | 100.0 | 70.4 ± 2.6 | 9.1 ± 1.5 | 0.0 | 21.7 ± 2.4 | 0.0 |
|
| 12.3 ± 2.3 | 0.0 | 100.0 | 70.0 ± 0.6 | 6.9 ± 1.8 | 0.0 | 27.0 ± 0.8 | 0.0 |
|
| 20.9 ± 2.2 | 3.9 ± 3.2 | 96.4 ± 1.5 | 67.4 ± 1.7 | 28.5 ± 1.1 | 0.0 | 13.6 ± 3.4 | 0.0 |
|
| 20.2 ± 3.1 | 4.1 ± 1.3 | 94.6 ± 2.1 | 65.5 ± 1.7 | 26.1 ± 1.4 | 0.0 | 14.7 ± 2.4 | 0.0 |
|
| 33.5 ± 1.4 | 0.0 | 89.7 ± 1.5 | 54.2 ±3.1 | 14.1 ± 1.9 | 0.0 | 20.2 ± 1.2 | 0.0 |
|
| 36.7 ± 2.1 | 0.0 | 90.0 ± 2.7 | 53.6 ± 2.4 | 15.1 ± 1.2 | 0.0 | 23.0 ± 2.3 | 0.0 |
|
| 30.7 ± 1.1 | 7.9 ± 1.2 | 93.5 ± 2.6 | 64.1 ± 1.2 | 30.7 ± 1.1 | 0.0 | 23.5 ± 2.6 | 0.0 |
|
| 41.2 ± 1.3 | 8.6 ± 2.2 | 100.0 | 81.4 ± 1.5 | 41.2 ± 1.3 | 0.0 | 26.4 ± 2.5 | 0.0 |
|
| 23.5 ± 2.4 | 0.0 | 76.8 ± 0.9 | 32.5 ± 2.0 | 7.1 ± 1.9 | 0.0 | 13.0 ± 0.5 | 0.0 |
|
| 18.3 ± 1.7 | 0.0 | 80.2 ± 1.5 | 45.7 ± 2.3 | 17.1 ± 2.2 | 0.0 | 26.5 ± 2.1 | 0.0 |
|
| 19.1 ± 2.2 | 0.0 | 27.6 ± 1.2 | 10.6 ± 1.2 | 20.3 ± 1.4 | 0.0 | 21.5 ± 2.2 | 0.0 |
|
| 18.5 ± 1.1 | 0.0 | 24.6 ± 1.4 | 9.6 ± 1.1 | 21.2 ± 1.5 | 0.0 | 23.4 ± 1.6 | 0.0 |
| Tioxazafen | 23.9 ± 3.3 | 12.6 ± 3.2 | 100.0 | 90.4 ± 0.7 | 13.5 ± 1.2 | 0.0 | 61.4 ± 1.7 | 8.8 ± 2.4 |
| Fosthiazate | 100.0 | 91.4 ± 2.5 | 100.0 | 100.0 | 72.4 ± 1.9 | 38.8 ± 1.3 | 38.4 ± 1.9 | 6.1 ± 3.1 |
| Fluopyram | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
a Each experiment was repeated three times.
Figure 5Scanning electron micrographs of S. sclerotiorum hyphae in untreated control (A) and treated with compound F15 (B) at 50 μg/mL.
In vitro IC50 values of the compound F15 and fluopyram against S. sclerotiorum SDH.
| Compound | IC50 (μg/mL) a | 95% Confidence Interval | Regression Equation | R |
|---|---|---|---|---|
|
| 12.5 ± 1.3 | 8.7–16.2 | y = −2.1x + 1.9 | 0.94 |
| Fluopyram | 7.9 ± 1.8 | 5.8–9.8 | y = −2.1x + 2.4 | 0.97 |
a Values are the mean ± standard deviation of 3 replicates.
Figure 6Virtual molecular docking comparisons of title compound F15 (A) and fluopyram (B) with SDH (PDB code: 2FBW). Hydrogen bond interactions are indicated by a green line, and the π–π interactions are indicated by a purple line.
The binding energies of compound F15 and fluopyram with SDH (kcal/mol).
| Compound | ΔEvdw | ΔEele | ΔEMM | ΔGsol | ΔEbind | −TΔS | ΔGbind a |
|---|---|---|---|---|---|---|---|
|
| −137.1 | −8.0 | −145.1 | 44.8 | −100.3 | 13.6 | −86.8 |
| Fluopyram | −143.7 | −8.9 | −152.1 | 55.3 | −96.9 | 8.8 | −88.1 |
a ΔGbind = ΔEele + ΔEvdw + ΔGsol + (−TΔS).
Figure 7Plots of the RMSDs of SDH with compound F15 and fluopyram during the 10 ns simulation.